TABLE 2.
Isolate name | City/country of origin | Underlying condition | Age | Gender | Sample origin | Antifungal prophylaxis | Antifungal treatment |
---|---|---|---|---|---|---|---|
CAPA 1 | Rennes, France | Chronic myeloid leukemia, ARDS | 79 | Female | BAL + tracheal aspiration | No | VCZ |
CAPA 2 | Rennes, France | Chronic myelo-monocytic leukemia, ARDS | 78 | Female | Tracheal aspiration | No | VCZ |
CAPA 3 | Rennes, France | ARDS | 75 | Male | Tracheal aspiration | No | VCZ |
CAPA 4 | Rennes, France | ARDS | 58 | Male | Tracheal aspiration | No | VCZ |
CAPA 5 | Rennes, France | ARDS | 78 | Female | Tracheal aspiration | No | VCZ |
CAPA 6 | Rennes, France | ARDS, obesity, hypertension | 71 | Male | Tracheal aspiration | No | VCZ |
CAPA 7 | Rennes, France | ARDS, hypertension | 73 | Male | Tracheal aspiration | No | VCZ |
CAPA 8 | Graz, Austria | ARDS | 65 | Male | Tracheal aspiration | No | IVZ |
CAPA 9 | Graz, Austria | ARDS | 60 | Male | BAL | Yes (PSZ) | IVZ |
CAPA 10 | Manchester, UK | ECMO | 41 | Male | BAL | No | VCZ |
CAPA 11 | Manchester, UK | ECMO | 41 | Male | BAL | No | VCZ |
ARDS, acute respiratory distress syndrome; CAPA, COVID-19 associated pulmonary aspergillosis; ECMO, extracorporeal membrane oxygenation; BAL, bronchoalveolar lavage; PSZ, posaconazole; VCZ, voriconazole; IVZ, isavuconazole. Note that CAPA 10 and 11 were isolated from the same patient.